TB Alliance and BioFocus Sign Compound Management Agreement
News Jan 11, 2010
BioFocus announced that it has signed a three year compound management agreement with the Global Alliance for TB Drug Development (TB Alliance).
Under this agreement BioFocus will manage TB Alliance’s chemical library collection. These services will be provided by BioFocus’ compound management facility in South San Francisco, USA.
“We are pleased to welcome TB Alliance as a new client to our compound management services, joining other prestigious names such as the National Institutes of Health,” said Scott Snyder, BioFocus’ Senior Director, Compound Management. “This collaboration leverages our full suite of compound management services and further expands our client base of not-for-profit discovery organizations to a global level.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE